Pretreatment of psoriasis with the vitamin D3 derivative tacalcitol increases the responsiveness to 311-nm ultraviolet B: Results of a controlled, right/left study [1]

British Journal of Dermatology

Volumn 144, Issue 3, 2001, Pages 628-629

  Messer, G ^a   Degitz, K ^a   Plewig, G ^a   Rocken M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL DERIVATIVE; TACALCITOL;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LETTER; MALE; PHOTOSENSITIZATION; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; ULTRAVIOLET B RADIATION; ULTRAVIOLET IRRADIATION;

ADULT; COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; DIHYDROXYCHOLECALCIFEROLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; ULTRAVIOLET THERAPY;

EID: 0035083768     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2001.04101.x     Document Type: Letter

References (7)

1. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial
2. The effect of long-term treatment with tacalcitol on the psoriatic epidermis: A flow cytometric analysis
3. A new development in UVB phototherapy of psoriasis
4. Combination phototherapy of psoriasis with calcipotriol and narrow-band UVB
5. Topical tacalcitol reduces the total UVB dosage in the treatment of psoriasis vulgaris
6. 3 derivatives and 311-nm-UVB
7. Augmentation of oral methoxsalen-photochemotherapy with an oral retinoic acid derivative